Firm misled investors on Alzheimer's drug, SEC charges.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 39361735.
- Also identified by DOI 10.1126/science.adt5694.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Agency fines Cassava Sciences $40 million for touting flawed research on simufilam.
Medical subject headings
- Alzheimer Disease
- Drug Industry
- Spiro Compounds
- Scientific Misconduct